FDA Should Require Cardiovascular Outcomes Trials For All Type 2 Diabetes Drugs, Panel Says

Endocrinologic and Metabolic Drugs Advisory Committee asks the agency to eliminate a degree of risk for all candidates, even if no safety signal emerges from the clinical program.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet